I now have comprehensive content. Here is the full breakdown:
Squamous Cell Carcinoma of the Lung
Overview
Squamous cell carcinoma (SCC) is one of the four major histologic types of lung carcinoma alongside adenocarcinoma, small cell carcinoma, and large cell carcinoma. It is classified as non-small cell lung cancer (NSCLC). Historically the most common lung cancer in men, it has been surpassed by adenocarcinoma as smoking rates have declined in the United States. - Robbins & Kumar Basic Pathology, p.485
Key USMLE Facts at a Glance
| Feature | Squamous Cell Carcinoma |
|---|
| Association | Strongest link to cigarette smoking |
| Location | Central - arises from bronchial epithelium, near the hilum |
| Precursor | Squamous metaplasia → dysplasia → carcinoma in situ → invasive SCC |
| Gross appearance | Hilar mass, often with cavitation |
| Histology | Keratin pearls + intercellular bridges (desmosomes) |
| IHC markers | p40, p63, CK5/6 positive |
| Paraneoplastic | PTH-rP → hypercalcemia (most classic) |
| Spread | Tends to be more locally invasive; slower to metastasize vs. others |
Pathogenesis / Precursor Lesions
SCC arises from bronchial epithelium and follows a well-defined stepwise progression:
- Goblet cell hyperplasia
- Basal (reserve) cell hyperplasia
- Squamous metaplasia
- Squamous dysplasia (mild → moderate → severe)
- Carcinoma in situ (CIS)
- Invasive squamous cell carcinoma
This progression is the clearest tumor-precursor sequence of all lung cancers and can be identified in the bronchial mucosa adjacent to a resected specimen. - Robbins Pathology, eFig. 11.6
Histology (H&E)
The classic histologic findings are:
- Keratin pearls (whorled nests of keratinizing cells)
- Intercellular bridges (desmosomes between cells)
- Sheets of cells (not the 3D glandular clusters of adenocarcinoma)
- Desmoplastic stromal response
- Well-differentiated tumors show extensive keratinization; poorly differentiated tumors may lose these features
From the textbook image (Fishman's, Fig. 111-7):
Fig. A: Desmoplastic response with infiltrating SCC nests. Fig. B: Keratinization and intercellular bridges (H&E, 200x). - Fishman's Pulmonary Diseases
Squamous cell carcinomas are morphologically identical to extrapulmonary SCC (e.g., head and neck SCC) and cannot be distinguished by immunohistochemistry alone. - Harrison's 22E, p.659
Immunohistochemistry
| Marker | SCC | Adenocarcinoma | SCLC |
|---|
| p40 / p63 | ✅ Positive | Negative | Negative |
| CK5/6 | ✅ Positive | Negative | Negative |
| TTF-1 | Negative | ✅ Positive | ✅ Positive |
| Napsin A | Negative | ✅ Positive | Negative |
| Synaptophysin/CD56 | Negative | Negative | ✅ Positive |
Paraneoplastic Syndromes
PTH-related peptide (PTH-rP) secretion causing hypercalcemia is the hallmark paraneoplastic syndrome of squamous cell carcinoma. This is a high-yield USMLE association.
From Robbins Table 11.6:
"Parathyroid hormone-related peptide (PTH-rp) [is produced by] squamous cell carcinoma"
Other paraneoplastic syndromes by lung cancer type (for comparison):
- SCLC: ACTH (Cushing's), ADH (SIADH), gastrin-releasing peptide, calcitonin, Lambert-Eaton syndrome
- Adenocarcinoma: Hypertrophic osteoarthropathy, clubbing
- SCC: PTH-rP → hypercalcemia
Molecular / Genetic Features
From Robbins Table 11.6 (NSCLC including SCC):
- 3p deletions: ~80%
- TP53 mutations: ~50%
- p16/CDKN2A mutations: ~50% (higher in NSCLC vs SCLC)
- RB mutations: ~20%
- KRAS mutations: Common in adenocarcinoma, rare in SCC
- EGFR mutations: Absent in SCC (important - SCC does NOT benefit from EGFR inhibitors like erlotinib/gefitinib)
- ALK fusions: Absent in SCC
- SCC-specific driver mutations: SOX2 amplification, FGFR1 amplification, DDR2 mutations, PIK3CA mutations
Location & Gross Pathology
- Central location: Arises near the hilum, from segmental or subsegmental bronchi
- Often presents as a hilar or perihilar mass on CXR/CT
- Can cause obstructive pneumonia or atelectasis distal to the blocked bronchus
- Tendency to cavitate (central necrosis) - SCC is the most common lung cancer to cavitate
- May cause hemoptysis (due to central location and erosion into vessels)
Clinical Features
Common presentations:
- Chronic cough, hemoptysis (central location erodes into bronchial vessels)
- Post-obstructive pneumonia - recurrent pneumonia in the same lobe
- Atelectasis from bronchial obstruction
- Hypercalcemia from PTH-rP (fatigue, polyuria, constipation, altered mentation)
Advanced disease:
- Horner syndrome (ptosis, miosis, anhidrosis, enophthalmos) - from apical (Pancoast) tumor invading cervical sympathetic plexus
- Pancoast syndrome - apical tumor with brachial plexus involvement + Horner + rib/vertebral destruction
- Superior vena cava (SVC) syndrome - compression of SVC causing facial plethora, arm swelling
- Hoarseness - left recurrent laryngeal nerve compression
- Phrenic nerve palsy causing elevated hemidiaphragm
- Spread to Virchow's node (left supraclavicular lymph node)
Spread & Metastasis
All lung cancers spread to:
- Regional lymph nodes (carinal, mediastinal, scalene, supraclavicular)
- Distant: brain, liver, adrenal glands, bone
SCC tends to metastasize later than adenocarcinoma and SCLC, making it more likely to be resectable at diagnosis.
"Overall, squamous cell carcinoma and adenocarcinoma carry a more favorable prognosis than small cell carcinoma." - Robbins & Kumar, p.487
SCLC vs. NSCLC Comparison (High-Yield Table)
| Feature | SCLC | NSCLC (SCC / Adeno) |
|---|
| Microscopy | Small cells, scant cytoplasm, fine chromatin, no nucleoli | Abundant cytoplasm, pleomorphic nuclei, coarse chromatin, prominent nucleoli |
| Neuroendocrine markers (chromogranin, synaptophysin, CD56) | Present | Absent |
| Mucin | Absent | Present (adenocarcinoma) |
| PTH-rP | Absent | Present (SCC) |
| Resectable? | Rarely | Yes (if localized) |
| Responds to chemo? | Yes (very sensitive) | Less so |
| 3p deletions | ~90% | ~80% |
| TP53 mutations | ~90% | ~50% |
| RB mutations | ~90% | ~20% |
Source: Robbins & Kumar Basic Pathology, Table 11.6
Screening & Staging
- Low-dose CT (LDCT) is recommended for high-risk individuals (heavy smokers, age 50-80 per USPSTF 2021 guidelines)
- Staging uses the TNM system
- At diagnosis: >50% already have distant metastases; ~25% have regional node involvement
- 5-year survival: ~20% overall; ~50% if disease is localized at diagnosis - Harrison's 22E
Treatment Principles
- Resectable disease (early stage): Lobectomy or pneumonectomy
- Locally advanced / unresectable: Concurrent chemoradiotherapy
- Advanced/metastatic SCC:
- First-line: Pembrolizumab (anti-PD-1) ± chemotherapy based on PD-L1 expression
- SCC does NOT have targetable EGFR/ALK mutations, so targeted therapy is not used
- Checkpoint inhibitors (PD-1/PD-L1 blockade) have improved outcomes
- Important: Bevacizumab (anti-VEGF) is contraindicated in SCC due to risk of fatal pulmonary hemorrhage
High-Yield USMLE Mnemonics
"SCC = Sentral, Smokers, Squames, hypercalCemia"
- Sentral (central location)
- Smokers (strongest smoking association among NSCLC)
- Squames = keratin pearls + intercellular bridges
- hyperCalcemia via PTH-rP
Cavitation lung cancers: SCC > Large cell (SCC most common to cavitate)
Location mnemonic: "SCC is Central, Adeno is pAripheral"